1. Home
  2. Search Clinical Trials
Search
Filters
Clear All
  • 16
  • 25
  • 1
  • 164

Phase

  • 1
  • 1
  • 1
  • 5
  • 4
  • 3
  • 152
  • 194
  • 64
  • 205
  • 1
  • 12
  • 2
  • 1
  • 205

Found 206 Neoplasm trials

A listing of Neoplasm medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Sort by:

International Phase 3 Trial in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ALL) Testing Imatinib in Combination With Two Different Cytotoxic Chemotherapy Backbones

2 years - 21 years
All genders
This randomized phase III trial studies how well imatinib mesylate and combination chemotherapy work in treating patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukemia.
Learn More

Risk-stratified Therapy for Acute Myeloid Leukemia in Down Syndrome

3 years or below
All genders
The purpose of this study is to treat for AML in Down Syndrome patients.
Learn More

A Phase III Randomized Trial for Newly Diagnosed High Risk B-Lymphoblastic Leukemia (B-ALL) Including a Stratum Evaluating Dasatinib (NSC#732517) in Patients With Ph-Like Tyrosine Kinase Inhibitor (TKI) Sensitive Mutations

1 years - 30 years
All genders
This randomized phase III trial is studying how well combination chemotherapy works in treating young patients with newly diagnosed acute lymphoblastic leukemia that is likely to come back or spread.
Learn More

Developing the Breast Cancer Self-Efficacy Scale for Partners (BCSES-P)

18 years - 100 years
Accepts healthy volunteer
All genders
Are you, or is someone you know, a partner of a breast cancer survivor?   Breast cancer can be a scary and hard situation for your significant other and for YOU. Partners experience a lot of stress after the diagnosis. Finding ways to help them is important. This study is …
Learn More

Risk-Stratified Randomized Phase III Testing of Blinatumomab (NSC#765986) in First Relapse of Childhood B-Lymphoblastic Leukemia (B-ALL)

1 years - 30 years
All genders
This randomized phase III trial compares how well blinatumomab works compared with standard combination chemotherapy in treating patients with B-cell acute lymphoblastic leukemia that has returned after a period of improvement (relapsed).
Learn More

An Open-label Multicenter Phase 2 Study Evaluating the Efficacy and Safety of Daratumumab in Pediatric and Young Adult Subjects >=1 and =30 Years of Age With Relapsed/Refractory Precursor B-cell or T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

1 years - 30 years
All genders
The purpose of this study is to see if Daratumumab is useful for treating pediatric (subjects aged >=1 to 18 years) and young adult patients (aged 18 to 30 years) with acute lymphoblastic leukemia or lymphoblastic lymphoma.
Learn More

Breast Cancer Survivors and Their Partners Needed for Research Study!

100 years or below
All genders
ARE YOU OR SOMEONE YOU KNOW A BREAST CANCER SURVIVOR?  We need your help! Researchers at Purdue University are looking for breast cancer survivors and their romantic partners to take part in a study exploring how relationships and stress affect couples' immune and cardiovascular systems during survivorship.Couples in survivorship who are living and …
Check Eligibility

Study of Testing in People Interested in Research Participation

Male
The purpose of this research study is to learn about testing in people who are interested in participating.Participants will take part in testing as part of the study.
Check Eligibility

Phase 3 Study of Nemvaleukin Alfa in Combination With Pembrolizumab in Patients With Platinum-Resistant Epithelial Ovarian Cancer (ARTISTRY-7)

18 years or above
Female
Phase 3
This is a Phase 3, multicenter, open-label, randomized study of nemvaleukin in combination with pembrolizumab versus protocol-specific Investigator's choice chemotherapy in patients with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer. Interested in participating? For more information about this research study or other cancer-related clinical trials at IU Simon Comprehensive …
Learn More

Managed Access Program (MAP) to Provide Access to CTL019, for ALL or DLBCL Patients With Out of Specification Leukapheresis Product and/or Manufactured Tisagenlecleucel Out of Specification for Commercial Release

100 years or below
All genders
The purpose of this Managed Access Program (MAP) Treatment Plan is to provide access to CTL019, for acute lymphoblastic leukemia (ALL) or diffuse large b-cell lymphoma (DLBCL) patients with out of specification leukapheresis product and/or manufactured tisagenlecleucel out of specification for commercial release where no overwhelming safety concerns has been …
Learn More
171 - 180 of 206